As of late, it has definitely been a great time to be an investor in Xeris Pharmaceuticals.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced a limited-time $0 copay offering for commercially eligible patients effective now through April 30, 2020 as a response to the COVID-19 pandemic.

Xeris Pharmaceuticals Inc (XERS) delivered earnings and revenue surprises of 3.26% and -7.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 0.81% and 144.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on March 25, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 500 shares of its common stock to one new employee under Xeris’ Inducement Equity Plan.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive topline results from its Phase 1b weight-based dosing study of diazepam intramuscular (IM) injection utilizing its proprietary XeriSol™ technology.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, reinforces the importance of Gvoke PFS for people with diabetes and encourages healthcare professionals to discuss having glucagon on hand with their at-risk patients.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it has extended its $0 copay offer for Gvoke™ Pre-Filled Syringe (PFS) for commercially eligible patients effective through May 31, 2020 as a response to the COVID-19 pandemic.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its first quarter 2020 financial results before the opening of the U.S. financial markets on Thursday, May 7, 2020. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial and operational results.

Shareholders of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) will be pleased this week, given that the stock price is up...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced financial results for the first quarter ended March 31, 2020, as well as pipeline and corporate highlights.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced financial results for the fourth quarter and full year 2019, as well as pipeline and corporate highlights.

The backlash against large public companies receiving government PPP loans continues to grow louder.

Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its fourth quarter and full year 2019 financial results before the opening of the U.S. financial markets on Wednesday, March 11, 2020. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial and operational results. The live webcast will be accessible on the Investors section of Xeris’ website, www.xerispharma.com.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive findings from the outpatient stage of a Phase 2 proof-of-concept study of its developmental ready-to-use (RTU) glucagon in patients who experience postprandial hypoglycemic episodes following bariatric surgery.

Ladies and gentlemen, thank you for standing by, and welcome to the Xeris Pharmaceuticals First Quarter 2020 Financial Results Conference Call. Paul will provide opening remarks, and Barry will review the financial results, then we'll open the line for questions.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced an exclusive agreement with Clinigen Group plc (AIM: CLIN, ‘Clinigen’) to manage the supply and distribution of Gvoke™ outside of the United States where Gvoke is not currently licensed.

Companies In The News Are: TTWO, XERS, SPLK, NAVB

Whilst it may not be a huge deal, we thought it was good to see that the Xeris Pharmaceuticals, Inc. (NASDAQ:XERS...